Biotech Startups in New York
5 Biotech companies in New York that have filed with the SEC.
Barnwell Bio, Inc.
Other TechnologyBarnwell Bio, Inc. is an innovative company dedicated to transforming animal health management through advanced environmental monitoring solutions. By addressing the critical issues of disease detection and health management in livestock, the company aims to reduce the substantial economic losses attributable to animal health challenges, which are estimated at $300 billion annually.
Founded 2024
Episteme Prognostics, Inc.
BiotechnologyEpisteme Prognostics, Inc. is a pioneering precision medicine company dedicated to revolutionizing pancreatic cancer diagnosis and treatment. By focusing on the development of groundbreaking diagnostic tests, the company aims to enhance therapeutic decisions, ultimately improving patient outcomes. Their innovative technology leverages epigenetic biomarkers to provide critical insights into treatment responses for patients diagnosed with this challenging disease.
Founded 2021
Liberation Labs Holdings Inc.
Other TechnologyLiberation Labs Holdings Inc. specializes in the commercialization of precision fermentation technology, focusing on the production of sustainable bioproducts. The company is dedicated to bridging the gap between innovative biotechnology advancements and their commercial-scale production, providing solutions that address the demand for environmentally friendly products.
Founded 2022
Medicovestor, Inc.
BiotechnologyMedicovestor is an early-stage biopharmaceutical company founded in 2023, focused on developing next-generation antibody-drug conjugate (ADC) platforms. The company aims to create precision medicines for solid tumors like pancreatic and ovarian cancer by overcoming the limitations of existing ADCs, particularly in tumors with low antigen expression.
Myrtelle Inc.
BiotechnologyMyrtelle Inc. is a clinical-stage gene therapy company carrying the mission of developing innovative treatments for neurodegenerative diseases that primarily affect myelin and white matter in the brain. With a particular focus on Canavan disease, the company addresses critical gaps in treatment options for rare genetic disorders of the central nervous system, aiming to improve patient outcomes significantly.
Founded 2021